AMRI has secured a seven-year contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH). AMRI’s activities under the contract (HHSN272201800008I) will focus on the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies. The bulk of AMRI’s work will occur at the company’s Albany, NY, facilities. “Our new contract with the NIH not only en...